Codex4SMEs - Companion Diagnostics expedited for SMEs

Project Summary

The Interreg project Codex4SMEs (Companion diagnostics expedited for small and medium-sized businesses) project plans to improve healthcare by enhanced adoption of Personalized Medicine in North-West Europe. The objective is to establish a network, which supports SMEs along the value chain of Companion diagnostics (Cdx) development.

Companion diagnostics (Cdx) are an indispensable tool for optimum application of Personalized Medicine: they allow tests to determine the molecular causes of a disease before treatment has started. However, thus far the development of companion diagnostics has been highly time-consuming and costly, so at present it is only used in the context of very few treatments.

Codex4SMEs will establish a transnational network of nine partners and two sub-partners from seven countries and expedite the development of the SMEs’ products in the field of Cdx. There is a need to improve SMEs‘ innovative capabilities and raise both international competitiveness and the impact of North-West Europe SMEs in this global market as the USA are far ahead - Codex4SMEs will directly address this challenge.


Benefits for SMEs

  • Access to:
    • Sample access service
    • biomarker validation service
    • knowledge transfer service of biomarker/biobanking
    • ecosystems from 11 partners
    • transnational roadshow to venture and large pharma companies
    • business model and expert access service for business growth and scaling
  • Tailored support dependent from the product TRL levels of the SMEs



Project events & news


The new era for prevention & Diagnostics - Opportunities for SMEs and Corporates

12-10-2021 – online

Stronger together. The EEN, the Interreg NWE projects Codex4SMEs, Boost4Health, MATMED, the COSME-project CELIS and the H2020-project Digi-B-Cube join forces to reach a new level o... Read more

View more


With Codex4SMEs from researching biomarkers to entering the market

Posted on 08-07-2021

On July 6th 2021 the online event „Biomarkers from Research to Market“ took place as part of the Interreg NWE project Codex4SMEs. Find here a recording of the session as well as th... Read more

Report about the Biomarkers' support by the Integrated Biobank of Luxembourg

Posted on 02-07-2021

Meet our Biomarker Scientist and Expert PhD Monica Marchese, Group Leader at LIH/IBBL, in this Video Interview! Read more

View more

Project Partners

  • BOM Holding BV, NL

    15 Goirlese Weg

    View partner details

  • Innovation and Management Centre Limited T/A WestBIC, IE

    Galway Technology Centre Mervue Business Park
    H91 E2W5

    View partner details

  • InnovationQuarter, NL

    32 Prinses Margrietplantsoen
    Den Haag

    View partner details

  • Medicen Paris Region, FR

    3-5 Impasse Reille

    View partner details

  • Integrated BioBank of Luxembourg, LU

    6 Rue Nicolas Ernest Barblé

    View partner details

  • Biobank Graz @ Medizinische Universität Graz, AT

    2 Auenbruggerplatz

    View partner details

  • EIT Health Germany GmbH, DE

    116 Sandhofer Strasse

    View partner details

  • European Research Infrastructure for Translational Medicine, NL

    1118 De Boelelaan
    1081 HZ

    View partner details

  • FlandersBio, BE

    13 Jean Baptiste de Ghellincklaan

    View partner details

  • BioRegio STERN Managment GmbH, DE

    10 Friedrichstrasse

    View partner details

Lead partner

Organisation Address Email Website
BioRegio STERN Managment GmbH, DE 10 Friedrichstrasse
Name Contact Name Email Country
BOM Holding BV, NL Maria Hein Netherlands
Innovation and Management Centre Limited T/A WestBIC, IE Eunan Cunningham Ireland
InnovationQuarter, NL Lonneke Baas Netherlands
Medicen Paris Region, FR Daniela Onofri France
Integrated BioBank of Luxembourg, LU Monica Marchese Luxembourg
Biobank Graz @ Medizinische Universität Graz, AT Pablo Zardoya Laguardia Austria
EIT Health Germany GmbH, DE Katharina Ladewig Germany
European Research Infrastructure for Translational Medicine, NL Emanuela Oldoni Netherlands
FlandersBio, BE Willem Dhooge Belgium



The Codex4SMEs project offers a tailored support scheme programme.

Services provided by the biobank project partners will be covered 100 % of the costs by the project.


Following services are still available within the project:

  • Knowledge Transfer Services (in biomarker & biobanking topics) provided by the Biobank Graz
  • Sample Access Service provided by the Biobank Graz

          Look into specific collections & cohorts here

          Samples for pilot projects

                 - to test or establish a new method

                - clinical samples from a maximum number of 5 patients

                - no ethics vote required

                - Results must not be published

          Samples for  research projects

                - sample access for research projects/biomarker research

               - clinical samples from a maximum number of 20 patients

               - valid ethics vote mandatory


Sample Access and Knowledge Transfer services will be available continously.

Please note: there is a limited number of services available and will be revised following a 'fist come first serve basis'.

For interested SMEs the guidelines and the application documents are available for download below.

Do not hesitate to get in contact with your local Codex4SMEs-partner and/or the Biobank of Graz directly (




Earlier in the project, the Integrated Biobank of Luxembourg (IBBL) offered a Biomarker validation serivce for the Codex4SMEs-community. Five SMEs were awarded with the service during two call periods:

  • First call period: Oktober 15th, 2018 till December 14th, 2018
  • Second call period: February 18th, 2019 until April 19th, 2019


For evaluation of the application forms and professional recommendations to the Codex4SMEs-consortium, an independent expert group was integrated.

The members were:

  • Marie Souleau, European Patent Attorney
  • Patrice Debre, Pitié- Salpêtrière Hospital, INSERM

The Codex4SMEs-consortium would like to thank the expert group for their support, their time for revising the applications and helping us selecting the winners!

Find out more about the award and the winners:

The Advisory Board acts as an observing body. They provide insights and recommendations on different topics in the framework of Cdx to support the project.

These are the members:

  • Andreas Baur, BioLAGO e.V.
  • Dr. Michael Steinwand, BioLAGO e.V.
  • Sylvain Lehmann, French society of Clinical Biology
  • Philippe Manivet, French society of Clinical Biology
  • Prof. Dr. Kurt Zatloukal, Medical University of Graz
  • Prof. Dr. Berthold Huppertz, Medical University of Graz
  • Florence Bietrix, EATRIS- ERIC
  • Eric Steinfelder, BBMRI- ERIC
  • Diarmuid Cahalan, Metabolomic Diagnostics
  • Ida Haisma, Leiden Bio Science Park
  • Eefje Dekkers, InnovationQuarter

The map gives an overview of companies which are active in the field of companion diagnostics in the partner regions. When you klick at one selected company, further information like the main activities or the contact datails are mentioned.

Be part of the Codex4SMEs network, contact your regional partner and get an entry on the map.




For Matchmaking opportunities with other key players of the diagnostics' sector, we establsihed a platform which will run until September 2021.

>> Sign up here for matchmaking

Benefit from the Codex4SMEs projekt and get tailored support depending on your product TRL level. Furthermore you get access to:

  • Sample access service
  • biomarker validation service
  • knowledge transfer service of biomarker/biobanking
  • ecosystems from 11 partners
  • transnational roadshow to venture and large pharma companies
  • business model and expert access service for business growth and scaling

In the field of companion diagnostics, and even broader: in the field of Lifesciences and Medical Technology, timelines of research to market are very long. To create a therapy for a disease, it takes 10 to 15 years.

A lot of SME’s working on these kind of developments need external money to proceed with their businesses. However in the venture capital world return on investment timelines are much shorter: around 5 to 7 years. The SME has no time to work on their product in the way they want to do it. Capacity is lacking for research and business development, because it goes towards financing, keeping stakeholders happy, and going from one investment round to another.

In an ideal world an investor has patience and waits for actual results of the company. Environmental impact should be of much more added value than ROI’s. And when there is patience, the SME will come up with much better results, because they have the time to invest in their product.  Current numbers of SME-successes with external investment,  can raise from 10% to 60%.

To realize this change, a change of attitude is necessary.  It is a slow process because assumptions how the venture capital works, have to be refuted. With this animation we want to plant a seed, and food for thought. So in the long term hopefully things can and will change. For more information contact:

The Codex4SMEs-partners have good contacts to other biobanks.


Please feel free to contact us, the Codex4SMEs-partners are happy to help you in facilitating your individual biobank service, such as follows:

  • Need for a higher amount of samples (>20 samples)
  • Need for specific sample requests not available via Biobank Graz and the related free sample access service
  • Need for additional support in clinical trial/study planning (not covered within free sample access service)

Please note: costs for samples and/or other activities from other than the Biobank of Graz cannot be covered by the project.



Biobanking and Biomolecular Resources Research Infrastructure – European Research Infrastructure Consortium, the pan-European infrastructure of national biobank networks (Homepage).

  • European research infrastructure for biobanking
  • Bringing together all the main players from the biobanking field – researchers, biobankers, industry, and patients to boost medical research.
  • Quality management services
  • Support with ethical, legal and societal issues
  • IT services:
    • Directory
      • Intended for all different types of users, providing aggregate information about biobanks and their sample/data collections.
    • Negotiator
      • Facilitating communication between researchers searching for samples/data and biobanks allowing refinmenet of their queries and once the search is done, to request samples
    • Locator
      • A tool for researchers looking for samples/data, enabling them to query available samples/data sets on the level of individual samples and/or data items, under development.
      • NOT a search tool for individual samples.
Finnish Biobank Cooperative (FINBB)

FINBB, as a member of BBMRI-ERIC, is a one-accessshop for effortless access to Finnish biobank materials and biodata:

Fingenious is a

  • Digital gateway to Finnish biobanks and biomedical research
  • Built to serve academic and industry researchers and to advance medical research globally
  • Provides a view of and access to biospecimens and data from all public biobanks in Finland, through a single point of contact

Feasibility and access costs (FINBB)

  • Initial feasibility service is free of charge.
  • Providing cost-estimation for the feasibility report if compiling the feasibility report requires exceptional effort and a significant amount of time
  • Submitting access requests through Fingenious is also free of charge. Questioner will receive a cost estimation of your biobank project during the feasibility and access request

Please find their homepage here.

Commercial Biobanks

In.vent Diagnostica GmbH

In.vent Diagnostica GmbH

  • Partner of all diagnostic Stakeholders for the procurement of biologic material of human origin (e.g., innovations, research, development, clinical studies, production, controls, standardisation, ...)
  • Active in the field of diagnostics
  • Targeted procurement of human biomaterials:
    • Standards & controls – high volumes possible
    • Quality control panels
    • Clinically defined samples
      • Highly specific parameters possible
      • Samples suitable for Clinical Performance Studies
      • Extensive global network of physicians and hospitals
  • Company owned study centre:
    • on demand blood donations
    • control over all steps of pre-analytics
  • Clinical services: Planning, Ethics, Samples, Performance Studies, Statistics, Reports (PER), Submission at NB

New calls for urgent research into coronavirus variants

Find out here:

The European Commision mobilises €123 million for research and innovation to combat the threat of variants

Reliable sources of information on the SARS-CoV-2:

As part of the Codex4SMEs-project, a Market Analysis Service was offered.


This service is no longer available and was successfully implemented in the project.


For further questions: please feel welcome to contact Marieke Huis in 't Veld:



Guide platform for regulatory and reimbursement issues

One critical hurdle for developers of (companion) diagnostics  is obtaining the right information on regulatory and reimbursement issues. In order to facilitate the access to such information, the Codex4SMEs project  provides SMEs from the field of (companion) diagnostics a list of information that compiles all relevant links on this topic.


Institution Description Type
Foundation for the National Institutes of Health (FNIH) The Biomarkers Consortium Biomarker R&D
Health and environmental sciences institute (HESI) Health and environmental sciences institute  Healthcare R&D
ISPOR France Medical Device - Global Health Technology Assessment Road Map Reimbursement and Regulatory
Personalized Medicine Coalition (PMC) Personalized Medicine in the Clinic Advocacy Group
Personalized Medicine Coalition (PMC) Advancing Access to Personalized Medicine: A Comparative Assessment of European Reimbursement Systems Advocacy Group
Personalized Medicine Coalition (PMC) Personalized Medicine at FDA: an annual research report Advocacy Group
Personalized Medicine Coalition (PMC) Personalized Medicine Coalition Advocacy Group

Institution Description Type
European Molecular Quality Network (EMQN) Not-for-profit community interest company (CIC) promoting quality in genetic testing by establishing, harmonising and disseminating best practice Best Practice
MTR Consulting Innovative payment schemes for medical technologies and in vitro diagnostic tests in Europe Reimbursement
MTR Consulting Challenges of the European market access function in a medical device company Market Access
MTR Consulting Key trends in European market access for medical technologies Market Access
European Union

Institution Description Type
Competent Authorities for Medical Devices (CAMD) CAMD Implementation Taskforce: Medical Devices Regulation/In-vitro Diagnostics Regulation (MDR/IVDR) Roadmap Regulatory
EuroGentest Harmonisation of genetic
testing across Europe 
European database on medical devices (EUDAMED) registration system, a collaborative system, a notification system, a dissemination system Regulatory
European In vitro diagnostic Regulation (IVDR) EGULATION (EU) 2017/746 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 5 April 2017 Regulatory
European Medical Agency (EMC) Scientific evaluation, supervision and safety monitoring of medicines in the EU Regulatory
European Medical Device Regulation (MDR) REGULATION (EU) 2017/745 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 5 April 2017 Regulatory
European Society of Human Genetics (ESHG) ESHG promotes research in basic and applied human and medical genetics Healthcare R&D
List of Notified Bodies Notified bodies responsible for the certification of IVD according to Regulation (EU) 2017/746 on in vitro diagnostic medical devices Regulatory

European Commission:

Medical Devices - Sector

Overview of European regulatory framework for medical devices and in vitro diagnostic medical devices. Regulatory



Institution Description Type
Alliance Aviesan et à ses membres, né des investissements d’Avenir (AVIESAN) BMK Tools for biomarker developers Biomarker R&D
Alliance nationale pour les sciences de la vie et de la santé (AVIESAN) French National Alliance for Life Sciences and Health: Coordination of national research policies Biomarker R&D
Haute Autorité de Santé (HAS) Recommendations that aid public authorities in reimbursement and pricing decision-making with regards to the French national health fund Reimbursement
Institut National du Cancer (INCA) French National Cancer Institute: health and science agency in charge of cancer control in France Regulatory
Agence nationale de sécurité du médicament et des produits de santé (ANSM)  National Agency for Medicines and Health Products Safety (France) Regulatory



Institution Description Type
Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) General information on the regulation of deployment of medical apps in Germany: Digitale-Versorgung-Gesetz  Regulatory
Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) Legal text of Digitale-Versorgung-Gesetz–DVG (Regulation of medical apps in Germany) Regulatory
DEKRA Notified Body responsible for IVD certification Regulatory
German Institute of Medical Documentation and Information (DIMDI) Notifications Medical Devices and In vitro Diagnostics Regulatory
Gemeinsame Bundesausschuss The federal joint Committee (G-BA) The federal joint Committee (G-BA): Reimbursement of Medical Devices and Drugs in Germany Reimbursement
Instituts für Qualität und Wirtschaftlichkeit im
Gesundheitswesen (IQWiG).
Institute for Quality and Efficiency in Health Care (IQWiG): IQWiG examines the advantages and disadvantages of medicine services - in certain cases also theirs costs, Reimbursement and Regulatory



Institution Description Type
Health Products Regulatory Authority (HPRA) Guide for Manufacturers of General Class In-Vitro Diagnostic Medical Devices  Regulatory
Health Products Regulatory Authority (HPRA) New EU Device Legislation Information Pack Regulatory
Health Products Regulatory Authority (HPRA) Key aspects specific to the in-vitro Diagnostics Regulation (IVDR) Regulatory


The Netherlands

Institution Description Type
Health and Youth Care Inspectorate Registration and deregistration of medical devices or IVD's Regulatory
United Kingdom

Institution Description Type
Medicines and Healthcare products Regulatory Agency (MHRA) In vitro diagnostic medical devices: guidance on legislation  Regulatory
Medicines and Healthcare products Regulatory Agency (MHRA) Medical devices: how to comply with the legal requirements. Placement of a medical device in the UK market. Regulatory

The Biomarker Commercialization guideline is online! Provided by our partner project 'Biomarker Commercialization'

>> BIC - guide

The BIC Guide supports academic researchers and SMEs when developing an in-vitro diagnostic biomarker invention to a commercial product. It provides guidance through the technology readiness levels (TRL) and covers the clinical, regulatory, and business aspects of the commercialization process. The tasks are described and partially supported by useful, downloadable documents. The guide supports the potential commercialization and guides you through dialogue with industrial partners.

Codex4SMEs is joing forces with other relatable projects

We invite you to profit from the support measures of other project's activities and have access to even more stakeholders and key players in Europe!

We are teaming up with the following projects:

BIC - Biomarker Commercialization

an Interreg Baltic Sea Region - Project

>> Project webpage


Your contact person:

Aalborg University Hospital

Valérie Daussin Laurent

Planning to commercialize your biomarker invention?

Thousands of candidate biomarkers are being discovered and the number of publications has exploded in recent years, but the discovery of a candidate biomarker is just the beginning of a long road to a commercial product.

Few findings enter to the specific assay development phase, pass the evaluation of analytical and clinical performance characteristics, and are eventually transformed into IVD assays, as biomarker development and commercialization is complicated, time consuming and expensive.

To support and help the commercialization process of new in vitro diagnostics (IVD)-applicable biomarkers, a set of tools and useful information was made available free of charge. The tools give structure and validation to biomarker research. They guide researchers and product developers through the technology readiness levels and remind about the clinical, regulatory, and business aspects of the innovation process.

The tools are only intended as guidance. They have been compiled to the best of our knowledge from a wide variety of sources, but cannot claim to be complete. Each new discovery or development is individual, therefore all information and mentioned standards have to be considered for the concrete individual case. As soon as possible, think of establishing a dialogue with specialists and experts in the field.

The tools are intended for researchers, SMEs and technology transfer offices and are available to all free of charge.

Choose a tool to get started:


an Interreg North-West-Europe - project

>> Project webpage


Your contact person:

Noord-Brabant Development Agency (BOM)

Ria Hein

+31 6 52 607 187


Connect to your clients in North-West Europe!

Looking for new contacts and clients in North-West Europe? Make sure that you are in the online database of Boost4Health!

Within Boost4Health we aim to connect SMEs and service providers, to help SMEs making the next step. SMEs out of the Boost4Health regions have access to vouchers. Vouchers to spend in North-West Europe, maybe at your organisation! Make sure you are visible now for those SMEs! They are looking for service providers in the field of Lifesciences and Medical Devices. The vouchers can be used for specific expertises in the field of e.g. market insight. Make use of this business opportunity and connect through Boost4Health and the database.

CELIS - Cluster Excellence in Life Sciences

CELIS is funded by the European Union’s COSME programme

>> Project homepage


Your contact person:

BioRN Cluster Management GmbH

Annalisa Zuccotti


CELIS is one of 13 European Strategic Cluster Partnerships for Excellence (ESCP-4x) selected under the European Cluster Excellence Programme as part of the European Commission’s COSME programme.
CELIS combines some of the world-class life science ecosystems in Europe: BioRN Life Science Cluster Rhine Neckar (Germany), Smart Hub Flemish-Brabant (Belgium), Biopeople: Denmark's Life Science Cluster (Denmark) and Tartu Biotechnology Park (Estonia).

The project helps clusters, networks and business and innovation support organisations to maximize opportunities linked to cross-sectoral and inter-regional cooperation and internationalisation. It offers them and their members unique opportunities to expand their relationships and to enhance public-private partnerships.



  • Twinning, networking, and joint collaboration activities to support SMEs (EventXchange) in the field of digitalisation, biomarkers, nano-electronics and multi-omics in the life sciences [more]
  • Financial support for short-term exchanges within Europe: ClusterXchange. The ClusterXchange programme is a new pilot programme to financially support short-term exchanges to better connect Europe’s industrial ecosystems. [more]
  • Cluster management skill development to boost excellence in delivering SME support

Share this

Tweet Share